Hongdong Gao

Dr. Hongdong Gao


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
HGHongdong Gao
Hongdong Gao
HNHinano Nishikubo
Hinano Nishikubo
DMDONGHENG MA
DONGHENG MA
JPJuncheng Pan
Juncheng Pan
TSTomoya Sano
Tomoya Sano
MYMasakazu Yashiro
Masakazu Yashiro
Cancer-associated fibroblasts (CAFs) are a key constituent of the tumor microenvironment. CAFs may affect the development of tumor cells. The critical role of CAFs in the tumor microenvironment is linked to their epigenetic modifications, as a stable yet reversible regulation of cellular phenotypes. Current evidence indicates that their formation and function are closely linked to epigenetic mechanisms. Existing research indicates that the epigenetic alteration abnormalities are triggered by metabolic cues and stabilize the acquired phenotype of CAFs. This process is associated with transcriptional changes and patient outcomes in various tumors, providing a biological rationale and translational potential for reprogramming CAFs. Understanding of epigenetic modifications in CAFs remain insufficient, while DNA methylation in CAFs can alter CAF states through multiple pathways and thereby influence tumor progression. It is necessary to investigate the unique, identifiable epigenetic signatures of CAF. As an epigenetic reader couple histone acetylation to high-output oncogenic transcription; meanwhile, noncoding RNAs modulate CAF formation and therapeutic responses via bidirectional crosstalk between tumor cells and stroma. The interactions between different epigenetic modifications and their underlying regulatory logic may play a crucial role in developing new therapeutic strategies. This review focuses on the roles of DNA methylation, histone acetylation, and enhancer reprogramming in CAFs.

9 February 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
DIDaiki Imanishi
Daiki Imanishi
HNHinano Nishikubo
Hinano Nishikubo
DMDONGHENG MA
DONGHENG MA
HGHongdong Gao
Hongdong Gao
TSTomoya Sano
Tomoya Sano
MYMasakazu Yashiro
Masakazu Yashiro
The tumor heterogeneity that is frequently observed in cancer tissues comprises not only cancer cells but also stromal cells in the tumor microenvironment. One of the major components of tumor stroma, i.e., cancer-associated fibroblasts (CAFs), play crucial roles in tumor progression and the tumor response to chemotherapy. The known subtypes of CAFs are antigen-presenting CAFs (apCAFs), myofibroblastic CAFs (myCAFs), and inflammatory CAFs (iCAFs). It has been speculated that (i) the heterogeneity of CAF subtypes might contribute to tumor progression; (ii) cell-to-cell interactions among CAF subtypes in tumors might be associated with the development of various types of carcinomas, and (iii) juxtracrine and/or paracrine signaling from CAFs may play important roles in this development. A clarification of the mechanisms that underlie the tumoral heterogeneity of CAFs could contribute to cancer treatment as precision medicine. This review explains the significance of CAF heterogeneity in tumor microenvironments, especially concerning the CAF subtypes.

15 November 2026 in Genes
Verified
Journal Article
Open access
PDF file
DMDONGHENG MA
DONGHENG MA
TSTomoya Sano
Tomoya Sano
HNHinano Nishikubo
Hinano Nishikubo
YFYukina Furukawa
Yukina Furukawa
KUKoki Uchiyama
Koki Uchiyama
MYMasakazu Yashiro
Masakazu Yashiro
Background: KRAS mutations occur in over 90% of pancreatic ductal adenocarcinomas (PDAC), and KRASG12D is the most frequent variant. G12D-selective inhibitors are now in clinical development, but computational pathology has so far predicted mutation status only at the gene level, leaving allele-specific prediction unexplored. Because genomic testing can be time-consuming and costly, a tool that predicts KRASG12D mutation status from routine hematoxylin and eosin (H&E) images could help identify patients for confirmatory molecular testing and potential treatment with KRASG12D inhibitors. Here we present a multi-scale framework that predicts KRASG12D status from H&E whole-slide images, with integration of computed tomography (CT). Methods: Two public cohorts (TCGA, CPTAC) formed the training set, and an independent external cohort (Osaka Metropolitan University Hospital) served as validation. We developed a dual-magnification pipeline. In the high-magnification branch, a pathology foundation model (CONCH v1.5) was fine-tuned with low-rank adaptation (LoRA) and an attention-based multiple-instance learning head on 20× patches; in the low-magnification branch, a generative image model encoded a whole-slide overview. The two branches were integrated by late fusion into a multi-scale pathomics model, which was further combined with a radiomics model of CT. Results: The multi-scale pathomics model reached a pooled internal test area under the receiver operating characteristic curve (AUC) of 0.611 and an external AUC of 0.701. In the external patients with CT, the combined model reached an AUC of 0.772, compared with 0.753 for pathomics alone. Conclusions: KRASG12D status leaves a signal in routine H&E images and CT of PDAC that deep learning can detect and that transfers to an independent institution. After prospective validation, the framework might help prioritize patients for KRAS testing.